Physician profile
Echo Browning
NPI 1871016287
$1,562.84
in general payments reported to CMS, 2019-2025
21 companies · $180 in 2025
The $180 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $147 · 2022: $341 · 2023: $567 · 2024: $328 · 2025: $180.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,076.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,075.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $180.96 | 2021-2024 | Sublocade |
| Uswm, LLC | $146.54 | 2021-2024 | Lucemyra, Zimhi |
| Abbvie INC. | $140.40 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $131.48 | 2021-2025 | Rexulti, Abilify Maintena |
| Gilead Sciences, INC. | $122.67 | 2023-2024 | Epclusa |
| Alkermes, INC. | $110.54 | 2022-2025 | Aristada, Lybalvi, Aristada Initio |
| Corium, LLC | $97.16 | 2021-2023 | Azstarys |
| Idorsia Pharmaceuticals US INC | $68.55 | 2023-2024 | Quviviq |
| Axsome Therapeutics, INC. | $64.73 | 2023-2025 | Auvelity |
| Vanda Pharmaceuticals INC. | $63.76 | 2022-2025 | Fanapt |
| Takeda Pharmaceuticals U.S.A., INC. | $57.48 | 2022-2023 | Trintellix |
| Antares Pharma, INC. | $55.85 | 2021-2023 | Nocdurna, Xyosted, Tlando |
| Lilly USA, LLC | $52.15 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $49.55 | 2022-2023 | Caplyta |
| Pfizer INC. | $46.16 | 2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braeburn INC. | $42.44 | 2023-2024 | Brixadi |
| Lundbeck LLC | $36.86 | 2022 | |
| Novo Nordisk INC | $32.63 | 2024 | Wegovy, Ozempic, Rybelsus |
| Almatica Pharma LLC | $28.05 | 2022-2023 | Sertraline Hcl, Loreev Xr |
| Corcept Therapeutics | $17.85 | 2024 | Korlym |
| Supernus Pharmaceuticals, INC. | $17.03 | 2023 | Qelbree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Echo Browning listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.